The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is one of the most profitable biotech stocks to invest in now. On July 23, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on BioMarin ...

Wolfe Research projects Palynziq sales of $648 million, compared to consensus estimates of $669 million, and maintains its bullish stance on BioMarin shares despite the potential for Sephience to ...